Abstract

BACKGROUND

Despite introduction of new chemotherapeutic agents, outcomes of patients with metastatic pancreatic cancer are still poor. Metabolically supported chemotherapy (MSCT) is a novel approach targeting dysregulated energy mechanism of the tumor cell.

OBJECTIVES

This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy (HBOT) in patients with metastatic pancreatic cancer.

METHOD

This retrospective observational study included 25 patients with metastatic pancreatic ductal carcinoma (stage IV) who received MSCT (either gemcitabine-based or FOLFIRINOX regimen administered concomitantly with induced hypoglycemia) plus ketogenic diet, hyperthermia, and HBOT combination. Survival outcomes were evaluated.

RESULTS

During the mean follow-up duration of 25.4 ± 19.3 months, median overall survival and median progression-free survival were 15.8 months (95% CI, 10.5-21.1) and 12.9 months (95% CI, 11.2-14.6), respectively. Age and gender did not have any effect on overall survival (p > 0.05 for all).

CONCLUSIONS

MSCT administered together with ketogenic diet, hyperthermia, and HBOT appears to be a viable option with the potential to improve survival outcomes in patients diagnosed with metastatic pancreatic cancer. Further research, particularly with larger comparative clinical trials, is warranted.

MeSH

Pancreatic Neoplasms, Hyperthermia, Neoplasms, Drug Therapy, Diet, Diet, Ketogenic, Hyperbaric Oxygenation, Therapeutics, Complementary Therapies, Chemotherapy

Cited by

• Bibliometric and visual analysis in the field of ketogenic diet on cancer from 2012 to 2021. Front Nutr, 2022
• Neuroendocrine Tumors: A Comprehensive Review on Nutritional Approaches. Cancers (Basel), 2022
• Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. Cancers (Basel), 2023
• Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. World J Gastrointest Oncol, 2021
• On the nutritional and therapeutic effects of ketone body D-β-hydroxybutyrate. Appl Microbiol Biotechnol, 2021
• Ketogenic Diet for Cancer: Critical Assessment and Research Recommendations. Nutrients, 2021
• Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes. Med Oncol, 2020
• Modulated Electrohyperthermia: A New Hope for Cancer Patients. Biomed Res Int, 2021
• Beneficial Diets and Pancreatic Cancer: Molecular Mechanisms and Clinical Practice. Front Oncol, 2021
• Management, Survival, and Costs of Pancreatic Cancer: Population-Based Observational Study in Catalonia. Int J Environ Res Public Health, 2023
• Effect of Ketogenic Diets on Body Composition and Metabolic Parameters of Cancer Patients: A Systematic Review and Meta-Analysis. Nutrients, 2022
• Ketogenic Diets in Pancreatic Cancer and Associated Cachexia: Cellular Mechanisms and Clinical Perspectives. Nutrients, 2021
• Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. Cancers (Basel), 2021
• Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients-A Single-Center Case-Control Study. Diseases, 2021
• The use of ketogenic diets in cancer patients: a systematic review. Clin Exp Med, 2022
• Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma. BMC Med, 2024
• Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study. Front Nutr, 2025
• Metabolically Supported Chemotherapy for Managing End-Stage Breast Cancer: A Complete and Durable Response. Cureus, 2021
• Insulin-Lowering Diets in Metastatic Cancer. Nutrients, 2022
• Nutraceuticals as Supportive Therapeutic Agents in Diabetes and Pancreatic Ductal Adenocarcinoma: A Systematic Review. Biology (Basel), 2023